Virtu Financial LLC trimmed its stake in shares of HTG Molecular Diagnostics Inc (NASDAQ:HTGM) by 24.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 32,191 shares of the medical research company’s stock after selling 10,473 shares during the period. Virtu Financial LLC owned about 0.11% of HTG Molecular Diagnostics worth $82,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of HTGM. BlackRock Inc. raised its holdings in shares of HTG Molecular Diagnostics by 322.8% during the second quarter. BlackRock Inc. now owns 73,044 shares of the medical research company’s stock worth $238,000 after acquiring an additional 55,769 shares during the period. Symmetry Peak Management LLC acquired a new stake in shares of HTG Molecular Diagnostics during the third quarter worth $429,000. Granite Point Capital Management L.P. acquired a new stake in shares of HTG Molecular Diagnostics during the third quarter worth $1,010,000. Russell Investments Group Ltd. acquired a new stake in shares of HTG Molecular Diagnostics during the third quarter worth $1,089,000. Finally, Private Wealth Partners LLC raised its holdings in shares of HTG Molecular Diagnostics by 11.1% during the third quarter. Private Wealth Partners LLC now owns 1,000,000 shares of the medical research company’s stock worth $5,050,000 after acquiring an additional 100,000 shares during the period. Institutional investors and hedge funds own 46.15% of the company’s stock.

A number of brokerages recently commented on HTGM. Zacks Investment Research lowered shares of HTG Molecular Diagnostics from a “buy” rating to a “hold” rating in a report on Tuesday, January 15th. Cantor Fitzgerald reissued a “buy” rating and issued a $7.00 price objective on shares of HTG Molecular Diagnostics in a research report on Friday, November 9th. HC Wainwright set a $8.00 price objective on shares of HTG Molecular Diagnostics and gave the company a “buy” rating in a research report on Thursday, December 6th. ValuEngine downgraded shares of HTG Molecular Diagnostics from a “buy” rating to a “hold” rating in a research report on Tuesday, December 18th. Finally, Craig Hallum began coverage on shares of HTG Molecular Diagnostics in a research report on Monday, November 12th. They issued a “buy” rating and a $8.00 price objective for the company. Two analysts have rated the stock with a hold rating and five have given a buy rating to the stock. HTG Molecular Diagnostics presently has an average rating of “Buy” and a consensus price target of $6.60.

Shares of HTGM opened at $2.19 on Wednesday. HTG Molecular Diagnostics Inc has a one year low of $2.03 and a one year high of $5.83. The company has a debt-to-equity ratio of 0.42, a current ratio of 7.13 and a quick ratio of 6.93.

HTG Molecular Diagnostics (NASDAQ:HTGM) last announced its quarterly earnings data on Thursday, November 8th. The medical research company reported ($0.17) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.01. HTG Molecular Diagnostics had a negative net margin of 74.94% and a negative return on equity of 83.42%. The company had revenue of $4.71 million during the quarter, compared to the consensus estimate of $5.14 million. As a group, analysts anticipate that HTG Molecular Diagnostics Inc will post -0.72 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another publication, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this news story can be viewed at https://www.dailypolitical.com/2019/02/06/htg-molecular-diagnostics-inc-htgm-shares-sold-by-virtu-financial-llc.html.

HTG Molecular Diagnostics Profile

HTG Molecular Diagnostics, Inc develops and markets products and services based on proprietary technology that facilitates the routine use of targeted molecular profiling. The company offers instrumentation (or platforms); consumables comprising assay kits; and software analytics that automate sample processing and profiles various molecular targets.

Featured Article: Net Income

Institutional Ownership by Quarter for HTG Molecular Diagnostics (NASDAQ:HTGM)

Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.